Fragasso Group Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Fragasso Group reduced its stake in Amgen by 0.02% during the most recent quarter end. The investment management company now holds a total of 20,232 shares of Amgen which is valued at $3,239,750 after selling 5 shares in Amgen , the firm said in a disclosure report filed with the SEC on Apr 11, 2016.Amgen makes up approximately 1.26% of Fragasso Group’s portfolio.

Amgen opened for trading at $160.15 and hit $160.39 on the upside on Friday, eventually ending the session at $160.13, with a gain of 0.01% or 0.01 points. The heightened volatility saw the trading volume jump to 28,24,303 shares. Company has a market cap of $120,432 M.

Other Hedge Funds, Including , Contravisory Investment Management reduced its stake in AMGN by selling 5,880 shares or 8.11% in the most recent quarter. The Hedge Fund company now holds 66,643 shares of AMGN which is valued at $10,671,544. Amgen makes up approx 3.11% of Contravisory Investment Management’s portfolio.Triangle Securities Wealth Management boosted its stake in AMGN in the latest quarter, The investment management firm added 70 additional shares and now holds a total of 12,475 shares of Amgen which is valued at $1,950,965. Amgen makes up approx 1.28% of Triangle Securities Wealth Management’s portfolio.Mai Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 114 additional shares and now holds a total of 83,135 shares of Amgen which is valued at $13,001,483. Amgen makes up approx 1.07% of Mai Capital Management’s portfolio.Jlb Associates Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 590 additional shares and now holds a total of 48,374 shares of Amgen which is valued at $7,565,210. Amgen makes up approx 2.23% of Jlb Associates Inc’s portfolio.Indiana Trust Investment Management Co boosted its stake in AMGN in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 2,159 shares of Amgen which is valued at $337,646. Amgen makes up approx 0.19% of Indiana Trust Investment Management Co’s portfolio.

On the company’s financial health, Amgen reported $2.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.29. The company had revenue of $5536.00 million for the quarter, compared to analysts expectations of $5534.94 million. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 EPS.

Investors should note that on Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.Shares were Reiterated by Argus on Feb 8, 2016 to “Buy” and Lowered the Price Target to $ 185 from a previous price target of $202 .Credit Suisse Initiated Amgen on Jan 20, 2016 to “Outperform”, Price Target of the shares are set at $205.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.